Allos has secured worldwide rights to arbaclofen, a selective GABA-B receptor agonist previously evaluated in multiple Phase II and III trials in ASD, Fragile X syndrome (FXS) and 16p11.2 deletion ...
Climbing episodes of wild type mice (right) and mice with 16p11.2 deletion (left) during the first 10 hours of the experiment. At the beginning of the trial, both mice climb to the lower part of the ...
Mouse models of neurodevelopmental disorders possess unique, sex-specific metabolic dysfunctions, according to a new study in eNeuro. Understanding the unique metabolic effects of each disorder in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback